blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2456427

EP2456427 - Hot-melt extruded controlled release dosage form [Right-click to bookmark this link]
Former [2012/22]HOT-MELT EXTRUDED CONTROLLED RELEASE DOSAGE FORM
[2014/36]
StatusNo opposition filed within time limit
Status updated on  08.01.2016
Database last updated on 02.09.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL
published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Grünenthal GmbH
Zieglerstrasse 6
52078 Aachen / DE
[2015/10]
Former [2012/22]For all designated states
Grünenthal GmbH
Zieglerstrasse 6
52078 Aachen / DE
Inventor(s)01 / BARNSCHEID, Lutz
Kornblumenweg 30
41239 Mönchengladbach / DE
02 / GALIA, Eric
Franz-Wallraff-Strasse 1
52078 Aachen / DE
 [2012/22]
Representative(s)Bülle, Jan, et al
Kutzenberger Wolff & Partner
Waidmarkt 11
50676 Köln / DE
[N/P]
Former [2015/10]Bülle, Jan, et al
Kutzenberger Wolff & Partner
Theodor-Heuss-Ring 23
50668 Köln / DE
Former [2012/22]Bülle, Jan, et al
Kutzenberger & Wolff Patentanwaltssozietät Theodor-Heuss-Ring 23
50668 Köln / DE
Application number, filing date10741907.921.07.2010
WO2010EP04459
Priority number, dateEP2009000949922.07.2009         Original published format: EP 09009499
[2012/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011009602
Date:27.01.2011
Language:EN
[2011/04]
Type: A1 Application with search report 
No.:EP2456427
Date:30.05.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 27.01.2011 takes the place of the publication of the European patent application.
[2012/22]
Type: B1 Patent specification 
No.:EP2456427
Date:04.03.2015
Language:EN
[2015/10]
Search report(s)International search report - published on:EP27.01.2011
ClassificationIPC:A61K9/20, A61K31/137
[2012/22]
CPC:
A61K9/2072 (EP,KR,US); A61K31/137 (EP,KR,US); A61K9/2031 (EP,KR,US);
A61K9/2054 (EP,KR,US); A61K9/2095 (EP,KR,US); A61P25/04 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/22]
Extension statesBANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:Heißschmelzextrudierte retardierte pharmazeutische Darreichungsform[2014/36]
English:Hot-melt extruded controlled release dosage form[2014/36]
French:Formule de dosage pharmaceutique extrudée thermofusible à libération prolongée[2014/36]
Former [2012/22]HEISSSCHMELZEXTRUDIERTE RETARD-DARREICHUNGSFORM
Former [2012/22]HOT-MELT EXTRUDED CONTROLLED RELEASE DOSAGE FORM
Former [2012/22]FORME GALÉNIQUE EXTRUDÉE À CHAUD À LIBÉRATION CONTRÔLÉE
Entry into regional phase22.02.2012National basic fee paid 
22.02.2012Designation fee(s) paid 
22.02.2012Examination fee paid 
Examination procedure06.05.2011Request for preliminary examination filed
International Preliminary Examining Authority: EP
22.02.2012Examination requested  [2012/22]
24.09.2014Communication of intention to grant the patent
15.01.2015Fee for grant paid
15.01.2015Fee for publishing/printing paid
15.01.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.09.2014
Opposition(s)07.12.2015No opposition filed within time limit [2016/06]
Fees paidRenewal fee
13.07.2012Renewal fee patent year 03
10.07.2013Renewal fee patent year 04
14.07.2014Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL04.03.2015
BG04.03.2015
CY04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MK04.03.2015
MT04.03.2015
RO04.03.2015
SE04.03.2015
SI04.03.2015
SK04.03.2015
SM04.03.2015
TR04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
IE21.07.2015
LU21.07.2015
[2018/46]
Former [2018/30]BG04.03.2015
CY04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MK04.03.2015
MT04.03.2015
RO04.03.2015
SE04.03.2015
SI04.03.2015
SK04.03.2015
SM04.03.2015
TR04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
IE21.07.2015
LU21.07.2015
Former [2017/38]BG04.03.2015
CY04.03.2015
CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MT04.03.2015
RO04.03.2015
SE04.03.2015
SI04.03.2015
SK04.03.2015
SM04.03.2015
TR04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
IE21.07.2015
LU21.07.2015
Former [2017/21]CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
MT04.03.2015
RO04.03.2015
SE04.03.2015
SI04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
IE21.07.2015
LU21.07.2015
Former [2016/33]CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
RO04.03.2015
SE04.03.2015
SI04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
IE21.07.2015
LU21.07.2015
Former [2016/15]CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
RO04.03.2015
SE04.03.2015
SI04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
LU21.07.2015
Former [2016/13]CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
MC04.03.2015
RO04.03.2015
SE04.03.2015
SI04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2016/12]CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
RO04.03.2015
SE04.03.2015
SI04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2016/07]CZ04.03.2015
DK04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
RO04.03.2015
SE04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2015/50]CZ04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
RO04.03.2015
SE04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
IS04.07.2015
PT06.07.2015
Former [2015/49]CZ04.03.2015
EE04.03.2015
FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
RO04.03.2015
SE04.03.2015
SK04.03.2015
NO04.06.2015
GR05.06.2015
PT06.07.2015
Former [2015/39]FI04.03.2015
HR04.03.2015
LT04.03.2015
LV04.03.2015
SE04.03.2015
NO04.06.2015
GR05.06.2015
Former [2015/37]FI04.03.2015
HR04.03.2015
LT04.03.2015
SE04.03.2015
NO04.06.2015
GR05.06.2015
Former [2015/36]FI04.03.2015
HR04.03.2015
LT04.03.2015
SE04.03.2015
NO04.06.2015
Former [2015/35]LT04.03.2015
NO04.06.2015
Cited inInternational search[A]DE4229085  (BOEHRINGER MANNHEIM GMBH [DE]) [A] 1-14 * claims 1-22 ** figures 1,2 *;
 [X]DE4446470  (BASF AG [DE]) [X] 1-14 * paragraph [0013] - paragraph [0048] * * claims 1-8 *;
 [X]DE102005005446  (GRUENENTHAL GMBH [DE]) [X] 1-14 * paragraph [0020] - paragraph [0105] * * claims 1-14 * * figure 1 *;
 [X]WO2007103286  (SPHERICS INC [US], et al) [X] 1-14 * claims 1-62 *
by applicantUS4940556
 US5198226
 US5427798
 US2003064099
 WO2004043967
 WO2005016313
 WO2005016314
 WO2005066183
 WO2005102286
 WO2006002883
 WO2006002884
 WO2006002886
 WO2006082097
 WO2006082099
    - NING WU ET AL., JOURNAL OF CONTROLLED RELEASE, (2005), vol. 102, pages 569 - 81
    - V.S. MANTHENA ET AL., AM J DRUG DELIV., (2004), vol. 2, no. 1, pages 43 - 57
    - MM CROWLEY ET AL., DRUG DEV IND PHARM, (2007), vol. 33, no. 9, pages 909 - 26
    - "Guidance for Industry - Bioavailability and Bioequivalence - Studies for Orally Administered Drug Products - General Considerations", FDA, BP, ANNOUNCED IN THE FEDERAL REGISTER, (20030319), vol. 68, no. 53
    - P.A. PROESCHEL ET AL., J DENT RES, (2002), vol. 81, no. 7, pages 464 - 468
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.